je.st
news
Tag: cancer
MSD Announces First Presentation of Data on the Investigational Use of Pembrolizumab in Patients with Advanced Gastric Cancer at ESMO 2014
2014-09-28 09:15:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Pembrolizumab monotherapy achieved 31 percent overall response rate in patients with PD-L1 positive, advanced gastric cancer Phase 2 study to be initiated in first quarter of 2015 (KEYNOTE-059) WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--MSD, known as Merck in the United States and Canada, today announced the first presentation of data on the investigational use of pembrolizumab the companys anti-PD-1 therapy in PD-L1 positive, advanced gastric cancer. The early findings presented showed an overall response rate (confirmed and unconfirmed) of 31 percent with pembrolizumab as monotherapy, as measured by investigator assessed, RECIST v1.1 (n= 12/39: 95% CI, 17-47). Language: English Contact: For MSDMedia:Ian McConnell, 973-901-5722orClaire Mulhearn, 908-423-7425orInvestors:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
data
advanced
presentation
Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014
2014-09-28 09:15:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. KEYTRUDA monotherapy achieved 31 percent overall response rate in patients with PD-L1 positive, advanced gastric cancer Phase 2 study to be initiated in first quarter of 2015 (KEYNOTE-059) WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data on the investigational use of KEYTRUDA (pembrolizumab) the companys anti-PD-1 therapy in PD-L1 positive, advanced gastric cancer. The early findings presented showed an overall response rate (confirmed and unconfirmed) of 31 percent with KEYTRUDA as monotherapy, as measured by investigator assessed, RECIST v1.1 (n= 12/39: 95% CI, 17-47). Language: English Contact: MerckMedia:Ian McConnell, 973-901-5722orClaire Mulhearn, 908-423-7425orInvestor:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
data
advanced
presentation
Researchers create ultra-sensitive graphene sensor that can detect cancer biomarkers
2014-09-25 20:20:36| Extremetech
A new graphene detector has just been developed which can potentially determine who has cancer and perhaps even in some cases, what kind. The secret to building it lies in a radical new method for processing graphene on silicon carbide substrates.
Tags: create
cancer
researchers
detect
Juara To Donate To Cancer and Careers
2014-09-25 07:00:00| Happi Breaking News
Special promotion for October.
ANN expands commitment to BCRF through annual Breast Cancer Awareness campaign
2014-09-24 15:55:23| Apparel - Topix.net
ANN INC. , the parent Company of Ann Taylor and LOFT, today announces its expanded commitment to The Breast Cancer Research Foundation through its annual Breast Cancer Awareness campaign and latest in-store and online promotions.
Tags: annual
ann
cancer
commitment
Sites : [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] next »